RecruitingNot ApplicableNCT04200391

Very Low Carbohydrate Diets and Glucagon Response in T1DM

Glucagon Response in Patients With Type 1 Diabetes Mellitus Following a Very Low Carbohydrate


Sponsor

Boston Children's Hospital

Enrollment

12 participants

Start Date

Jan 3, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Despite major technological advances, management of type one diabetes mellitus (T1D) remains suboptimal, putting millions of people at risk for immediate and long-term complications. After meals, a mismatch between carbohydrate absorption rate and insulin action typically leads to alternating periods of hyper- and hypoglycemia. A conceptually promising approach to control both problems is dietary carbohydrate restriction to reduce postprandial blood glucose changes and insulin needs. In a prior survey study, the investigators documented exceptional glycemic control (HbA1c 5.67%) and low acute complication rates among 316 children and adults with T1D consuming a very-low-carbohydrate (VLC) diet. Despite these promising preliminary results, the use of VLC diets for T1D remain controversial, because of their restrictive nature and theoretical concerns regarding growth, ketoacidosis and hypoglycemia risks and efficiency of glucagon treatment for hypoglycemia. Glucagon is used as a rescue medication during severe hypoglycemia and increases blood glucose levels by mobilizing liver glycogen stores. If these stores are depleted during carbohydrate restriction, glucagon response may be inadequate and put individuals at risk for refractory hypoglycemia. A physiologic study has shown a blunted but still adequate response to glucagon in n=10 participants after following a VLCD for 1 week. Longer-term studies have not been done. To test the hypotheses that glucagon response remains adequate while following a VLC diet in the longer term, the investigators will conduct a glucagon challenge in participants who are assigned to the VLC arm of a randomized-controlled feeding study in 32 young adults with T1D who will receive a VLC vs a standard diet for 12 weeks. After an overnight fast, twelve participants in the VLC arm will receive IV insulin to lower blood glucose levels to 60 mg/dL, followed by a glucagon injection and monitoring of blood glucose levels and other metabolic fuels.


Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how a very low carbohydrate (ketogenic-style) diet affects the glucagon response and blood sugar control in adults with Type 1 diabetes (T1DM), using continuous glucose monitors and insulin pumps. **You may be eligible if...** - You have had Type 1 diabetes for at least 1 year - You are 18 to 40 years old - You use both a continuous glucose monitor (CGM) and an insulin pump - Your blood sugar control is reasonably stable (HbA1c between 6.5% and 9%) - You have had at least one diabetes care visit in the past 12 months **You may NOT be eligible if...** - You have had diabetic ketoacidosis or a severe low blood sugar episode in the past 6 months - You have dietary restrictions incompatible with the study meals (e.g., celiac disease, gastroparesis, certain allergies) - You are following a weight-loss or restrictive diet - You exercise vigorously more than 2 hours on more than 3 days per week - You have a history of an eating disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERVery low carbohydrate diet

All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance. The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein.


Locations(1)

Boston Children's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04200391


Related Trials